Percutaneous coronary intervention enoxaparin: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
/* 2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention: Enoxaparin{{cite journal |author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri... |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention | ==2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)<ref name="pmid22070837">{{cite journal |author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=24 |pages=2550–83 |year=2011 |month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref>== | ||
===Enoxaparin (DO NOT EDIT)<ref name="pmid22070837">{{cite journal |author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions |journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=24|pages=2550–83 |year=2011|month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref>=== | |||
{|class="wikitable" | {|class="wikitable" | ||
| Line 28: | Line 30: | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Performance of [[Unstable angina / non ST elevation myocardial infarction recommendations for PCI|PCI]] with [[enoxaparin]] may be reasonable in patients either treated with ''upstream'' [[enoxaparin|subcutaneous enoxaparin]] for [[Unstable angina / non ST elevation myocardial infarction|UA/NSTEMI]] or who have not received prior [[Unstable angina / non ST elevation myocardial infarction anticoagulant therapy|antithrombin therapy]] and are administered [[enoxaparin|intravenous enoxaparin]] at the time of [[Unstable angina / non ST elevation myocardial infarction recommendations for PCI|PCI]].<ref name="pmid20578166">{{cite journal |author=Brieger D, Collet JP, Silvain J, Landivier A, Barthélémy O, Beygui F, Bellemain-Appaix A, Mercadier A, Choussat R, Vignolles N, Costagliola D, Montalescot G |title=Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention |journal=[[Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions]] |volume=77|issue=2 |pages=182–90 |year=2011 |month=February |pmid=20578166 |doi=10.1002/ccd.22674|url=http://dx.doi.org/10.1002/ccd.22674 |accessdate=2011-12-15}}</ref><ref name="pmid12475453">{{cite journal |author=Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, Drobinski G, Sotirov I, Thomas D |title=A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention |journal=[[Journal of the American College of Cardiology]] |volume=40 |issue=11 |pages=1943–50 |year=2002 |month=December |pmid=12475453 |doi=|url=http://linkinghub.elsevier.com/retrieve/pii/S0735109702025317|accessdate=2011-12-15}}</ref><ref name="pmid15238590">{{cite journal |author=Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H |title=Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial |journal=[[JAMA :the Journal of the American Medical Association]] |volume=292 |issue=1 |pages=45–54 |year=2004|month=July |pmid=15238590 |doi=10.1001/jama.292.1.45 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=15238590 |accessdate=2011-12-15}}</ref><ref name="pmid19926048">{{cite journal|author=Montalescot G, Gallo R, White HD, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR |title=Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial |journal=[[JACC. Cardiovascular Interventions]] |volume=2 |issue=11 |pages=1083–91|year=2009 |month=November |pmid=19926048 |doi=10.1016/j.jcin.2009.08.016|url=http://linkinghub.elsevier.com/retrieve/pii/S1936-8798(09)00581-0|accessdate=2011-12-15}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Performance of [[Unstable angina / non ST elevation myocardial infarction recommendations for PCI|PCI]] with [[enoxaparin]] may be reasonable in patients either treated with ''upstream'' [[enoxaparin|subcutaneous enoxaparin]] for [[Unstable angina / non ST elevation myocardial infarction|UA/NSTEMI]] or who have not received prior [[Unstable angina / non ST elevation myocardial infarction anticoagulant therapy|antithrombin therapy]] and are administered [[enoxaparin|intravenous enoxaparin]] at the time of [[Unstable angina / non ST elevation myocardial infarction recommendations for PCI|PCI]].<ref name="pmid20578166">{{cite journal |author=Brieger D, Collet JP, Silvain J, Landivier A, Barthélémy O, Beygui F, Bellemain-Appaix A, Mercadier A, Choussat R, Vignolles N, Costagliola D, Montalescot G |title=Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention |journal=[[Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions]] |volume=77|issue=2 |pages=182–90 |year=2011 |month=February |pmid=20578166 |doi=10.1002/ccd.22674|url=http://dx.doi.org/10.1002/ccd.22674 |accessdate=2011-12-15}}</ref><ref name="pmid12475453">{{cite journal |author=Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, Drobinski G, Sotirov I, Thomas D |title=A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention |journal=[[Journal of the American College of Cardiology]] |volume=40 |issue=11 |pages=1943–50 |year=2002 |month=December |pmid=12475453 |doi=|url=http://linkinghub.elsevier.com/retrieve/pii/S0735109702025317|accessdate=2011-12-15}}</ref><ref name="pmid15238590">{{cite journal |author=Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H |title=Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial |journal=[[JAMA :the Journal of the American Medical Association]] |volume=292 |issue=1 |pages=45–54 |year=2004|month=July |pmid=15238590 |doi=10.1001/jama.292.1.45 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=15238590 |accessdate=2011-12-15}}</ref><ref name="pmid19926048">{{cite journal|author=Montalescot G, Gallo R, White HD, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR |title=Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial |journal=[[JACC. Cardiovascular Interventions]] |volume=2 |issue=11 |pages=1083–91|year=2009 |month=November |pmid=19926048 |doi=10.1016/j.jcin.2009.08.016|url=http://linkinghub.elsevier.com/retrieve/pii/S1936-8798(09)00581-0|accessdate=2011-12-15}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 16:11, 5 November 2012
|
Percutaneous Coronary Intervention Guidelines Microchapters |
|
PCI Approaches: |
|---|
|
CAD Revascularization: |
|
Pre-procedural Considerations: |
|
Procedural Considerations: |
|
|
|
|
|
|
|
|
|
|
Post-Procedural Considerations: |
|
Quality and Performance Considerations: |
|
Percutaneous coronary intervention enoxaparin On the Web |
|
American Roentgen Ray Society Images of Percutaneous coronary intervention enoxaparin |
|
Directions to Hospitals Treating Percutaneous Coronary Intervention |
|
Risk calculators and risk factors for Percutaneous coronary intervention enoxaparin |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)[1]
Enoxaparin (DO NOT EDIT)[1]
| Class I |
| "1. An additional dose of 0.3 mg/kg intravenous enoxaparin should be administered at the time of PCI to patients who have received fewer than 2 therapeutic subcutaneous doses (e.g., 1 mg/kg) or received the last subcutaneous enoxaparin dose 8 to 12 hours before PCI.[2][3][4][5][6] (Level of Evidence: B)" |
| Class III (Harm) |
| "1. Unfractionated heparin (UFH) should not be given to patients already receiving therapeutic subcutaneous enoxaparin.[2][7] (Level of Evidence: B)" |
| Class IIb |
| "1. Performance of PCI with enoxaparin may be reasonable in patients either treated with upstream subcutaneous enoxaparin for UA/NSTEMI or who have not received prior antithrombin therapy and are administered intravenous enoxaparin at the time of PCI.[8][9][2][10] (Level of Evidence: B)" |
References
- ↑ 1.0 1.1 Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011). "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions" (PDF). Journal of the American College of Cardiology. 58 (24): 2550–83. doi:10.1016/j.jacc.2011.08.006. PMID 22070837. Retrieved 2011-12-08. Text "PDF" ignored (help); Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 2.2 Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H (2004). "Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial". JAMA : the Journal of the American Medical Association. 292 (1): 45–54. doi:10.1001/jama.292.1.45. PMID 15238590. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Cohen M, Levine GN, Pieper KS, Lan L, Antman EM, Aylward PE, White HD, Kleiman NS, Califf RM, Mahaffey KW (2010). "Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial". Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions. 75 (6): 928–35. doi:10.1002/ccd.22340. PMID 20432399. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Collet JP, Montalescot G, Golmard JL, Tanguy ML, Ankri A, Choussat R, Beygui F, Drobinski G, Vignolles N, Thomas D (2004). "Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes". American Heart Journal. 147 (4): 655–61. doi:10.1016/j.ahj.2003.10.019. PMID 15077081. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Levine GN, Ferrando T (2004). "Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention" (PDF). Journal of Thrombosis and Thrombolysis. 17 (3): 167–71. doi:10.1023/B:THRO.0000040484.99422.77. PMID 15353913. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, Ozoux ML, Pensyl CE, Bigonzi F (2004). "Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study". Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions. 61 (2): 163–70. doi:10.1002/ccd.10726. PMID 14755805. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Drouet L, Bal dit Sollier C, Martin J (2009). "Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study". American Heart Journal. 158 (2): 177–84. doi:10.1016/j.ahj.2009.05.022. PMID 19619692. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Brieger D, Collet JP, Silvain J, Landivier A, Barthélémy O, Beygui F, Bellemain-Appaix A, Mercadier A, Choussat R, Vignolles N, Costagliola D, Montalescot G (2011). "Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention". Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions. 77 (2): 182–90. doi:10.1002/ccd.22674. PMID 20578166. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, Drobinski G, Sotirov I, Thomas D (2002). "A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention". Journal of the American College of Cardiology. 40 (11): 1943–50. PMID 12475453. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Montalescot G, Gallo R, White HD, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR (2009). "Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial". JACC. Cardiovascular Interventions. 2 (11): 1083–91. doi:10.1016/j.jcin.2009.08.016. PMID 19926048. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help)